Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Background: About one third of patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) treated with autologous anti-CD19 CAR T-cell therapy achieve a partial response (PR) or a stable disease (SD) on day 30 (D30) PET-CT scan. Among these patients, only 30% will convert later to a complete response (CR), while 70% will eventually progress, experiencing significantly poor outcomes. Therefore, early identification of patients with D30 PR at risk for subsequent progression is of utmost importance and could allow for the development of novel consolidation strategies.